lunes, 1 de julio de 2013

ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing : Genetics in Medicine : Nature Publishing Group

ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing : Genetics in Medicine : Nature Publishing Group

ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing

Genetics in Medicine
(2013)
doi:10.1038/gim.2013.73
Received
Accepted
Published online

Abstract

In clinical exome and genome sequencing, there is a potential for the recognition and reporting of incidental or secondary findings unrelated to the indication for ordering the sequencing but of medical value for patient care. The American College of Medical Genetics and Genomics (ACMG) recently published a policy statement on clinical sequencing that emphasized the importance of alerting the patient to the possibility of such results in pretest patient discussions, clinical testing, and reporting of results. The ACMG appointed a Working Group on Incidental Findings in Clinical Exome and Genome Sequencing to make recommendations about responsible management of incidental findings when patients undergo exome or genome sequencing. This Working Group conducted a year-long consensus process, including an open forum at the 2012 Annual Meeting and review by outside experts, and produced recommendations that have been approved by the ACMG Board. Specific and detailed recommendations, and the background and rationale for these recommendations, are described herein. The ACMG recommends that laboratories performing clinical sequencing seek and report mutations of the specified classes or types in the genes listed here. This evaluation and reporting should be performed for all clinical germline (constitutional) exome and genome sequencing, including the “normal” of tumor-normal subtractive analyses in all subjects, irrespective of age but excluding fetal samples. We recognize that there are insufficient data on penetrance and clinical utility to fully support these recommendations, and we encourage the creation of an ongoing process for updating these recommendations at least annually as further data are collected.
Genet Med advance online publication 20 June 2013
View full text

Keywords:

genome; genomic medicine; incidental findings; personalized medicine; secondary findings; sequencing; whole exome; whole genome

References

  1. Mayer AN, Dimmock DP, Arca MJ, et al. A timely arrival for genomic medicine. Genet Med 2011;13:195–196.
  2. Manolio TA, Chisholm RL, Ozenberger B, et al. Implementing genomic medicine in the clinic: the future is here. Genet Med 2013;15:258–267.
  3. Biesecker LG. Opportunities and challenges for the integration of massively parallel genomic sequencing into clinical practice: lessons from the ClinSeq project. Genet Med 2012;14:393–398.
  4. Green R, Rehm HL, Kohane I. Clinical genome sequencing. In: Ginsburg G, Willard H (eds). Genomic and Personalized Medicine. In press. Elsevier: San Diego.
  5. Wolf SM, Crock BN, Van Ness B, et al. Managing incidental findings and research results in genomic research involving biobanks and archived datasets. Genet Med 2012;14:361–384.
  6. Knoppers BM, Deschenes M, Zawati MH, Tasse AM. Population studies: return of research results and incidental findings Policy Statement. Eur J Hum Genet 2012;21:245–247.
  7. Fullerton SM, Wolf WA, Brothers KB, et al. Return of individual research results from genome-wide association studies: experience of the Electronic Medical Records and Genomics (eMERGE) Network. Genet Med 2012;14:424–431.
  8. Simon CM, Williams JK, Shinkunas L, Brandt D, Daack-Hirsch S, Driessnack M. Informed consent and genomic incidental findings: IRB chair perspectives. J Empir Res Hum Res Ethics 2011;6:53–67.
  9. Van Ness B. Genomic research and incidental findings. J Law Med Ethics 2008;36(2):292–297, 212.
  10. Green RC, Berg JS, Berry GT, et al. Exploring concordance and discordance for return of incidental findings from clinical sequencing. Genet Med 2012;14:405–410.
  11. Berg JS, Khoury MJ, Evans JP. Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time. Genet Med 2011;13:499–504.
  12. Kohane IS, Hsing M, Kong SW. Taxonomizing, sizing, and overcoming the incidentalome. Genet Med 2012;14:399–404.
  13. Berg JS, Adams M, Nassar N, et al. An informatics approach to analyzing the incidentalome. Genet Med 2013;15:36–44.
  14. Lohn Z, Adam S, Birch P, Townsend A, Friedman J. Genetics professionals’ perspectives on reporting incidental findings from clinical genome-wide sequencing. Am J Med Genet A 2013;161:542–549.
  15. American College of Medical Genetics and Genomics. Points to consider in the clinical application of genomic sequencing. Genet Med 2012;14:759–761.
  16. Westbrook JI, Braithwaite J, McIntosh JH. The outcomes for patients with incidental lesions: serendipitous or iatrogenic? AJR Am J Roentgenol 1998;171:1193–1196.
  17. Anastasova V, Blasimme A, Julia S, Cambon-Thomsen A. Genomic incidental findings: reducing the burden to be fair. Am J Bioeth 2013;13:52–54.
  18. Parker LS. The future of incidental findings: should they be viewed as benefits? J Law Med Ethics 2008;36:341–351, 213.
  19. Angrist M. You never call, you never write: why return of ‘omic’ results to research participants is both a good idea and a moral imperative. Per Med 2011;8:651–657.
  20. Richards CS, Bale S, Bellissimo DB, et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med 2008;10:294–300.
  21. Beskow L, Burke W. Offering individual genetic research results: context matters. Sci Transl Med 2010;2(38):20–38.
  22. Costain G, Bassett AS. Incomplete knowledge of the clinical context as a barrier to interpreting incidental genetic research findings. Am J Bioeth 2013;13:58–60.
  23. American Society of Human Genetics Board of Directors and American College of Medical Genetics Board of Directors. Points to consider: ethical, legal, and psychosocial implications of genetic testings in children and adolescents. Am J Hum Genet 1995;57:1233–1241.
  24. Committee on Bioethics. Ethical and policy issues in genetic testing and screening of children. Pediatrics 2013;131:620–622.
  25. Ross LF, Saal HM, David KL, Anderson RR. Technical report: ethical and policy issues in genetic testing and screening of children. Genet Med 2013;15:234–245.
  26. Wilfond B, Ross LF. From genetics to genomics: ethics, policy, and parental decision-making. J Pediatr Psychol 2009;34:639–647.
  27. Morrison AS. Screening in Chronic Disease. Oxford University Press: New York, 1985.
  28. Khoury MJ, McCabe LL, McCabe ER. Population screening in the age of genomic medicine. N Engl J Med 2003;348:50–58.
  29. Khoury MJ, Berg A, Coates R, Evans J, Teutsch SM, Bradley LA. The evidence dilemma in genomic medicine. Health Aff (Millwood) 2008;27:1600–1611.
  30. Khoury MJ. Public health genomics: the end of the beginning. Genet Med 2011;13:206–209.
  31. Pyeritz RE. The coming explosion in genetic testing–is there a duty to recontact? N Engl J Med 2011;365:1367–1369.
  32. Fritz A, Farrell P. Estimating the annual number of false negative cystic fibrosis newborn screening tests. Pediatr Pulmonol 2012;47:207–208.
  33. Johnston JJ, Rubinstein WS, Facio FM, et al. Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am J Hum Genet 2012;91:97–108.
  34. Saunders CJ, Miller NA, Soden SE, et al. Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units. Sci Transl Med 2012;4(154):135–154.
  35. Kwon JM, Steiner RD. “I’m fine; I’m just waiting for my disease”: the new and growing class of presymptomatic patients. Neurology 2011;77:522–523.
  36. Wright C, Burton H, Hall A, et al. Next Steps in the Sequence: The Implications of Whole Genome Sequencing for Health in the UK 2011. 978-1-907198-08-3.
Download references

Author information

Affiliations

  1. Division of Genetics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA

    • Robert C. Green &
    • Sarah S. Kalia

  2. Partners Healthcare Center for Personalized Genetic Medicine, Boston, Massachusetts, USA

    • Robert C. Green &
    • Heidi L. Rehm

  3. Department of Genetics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA

    • Jonathan S. Berg &
    • Julianne M. O’Daniel

  4. Division of Medical Genetics, Department of Human Genetics, UCLA School of Medicine, Los Angeles, California, USA

    • Wayne W. Grody

  5. Division of Molecular Pathology, Department of Pathology & Laboratory Medicine, UCLA School of Medicine, Los Angeles, California, USA

    • Wayne W. Grody

  6. Division of Pediatric Genetics, Department of Pediatrics, UCLA School of Medicine, Los Angeles, California, USA

    • Wayne W. Grody

  7. Department of Genetics, University of Alabama, Birmingham, Alabama, USA

    • Bruce R. Korf

  8. Autism and Developmental Medicine Institute, Geisinger Health System, Danville, Pennsylvania, USA

    • Christa L. Martin

  9. Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas, USA

    • Amy L. McGuire

  10. Division of Genomic Medicine, Department of Medicine, and Institute for Human Genetics, University of California, San Francisco, San Francisco, California, USA

    • Robert L. Nussbaum

  11. Department of Genetics, Stanford University, Stanford, California, USA

    • Kelly E. Ormond

  12. Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA

    • Heidi L. Rehm

  13. American College of Medical Genetics and Genomics, Bethesda, Maryland, USA

    • Michael S. Watson

  14. Genomic Medicine Institute, Geisinger Health System, Danville, Pennsylvania, USA

    • Marc S. Williams

  15. National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA

    • Leslie G. Biesecker

  16. Disclaimer: These recommendations are designed primarily as an educational resource for medical geneticists and other health-care providers to help them provide quality medical genetic services. Adherence to these recommendations does not necessarily ensure a successful medical outcome. These recommendations should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, geneticists and other clinicians should apply their own professional judgment to the specific clinical circumstances presented by the individual patient or specimen. It may be prudent, however, to document in the patient’s record the rationale for any significant deviation from these recommendations.

Corresponding authors

Correspondence to:
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)